Standalone and Consolidated Financial Results for FY 25-26
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts more than Nifty Microcap 250 and 2.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Makers Laboratories reported mixed results for FY 2025-26. On standalone basis, the company swung to a loss of Rs 171.98 Lacs versus profit of Rs 464.11 Lacs in FY25, due to higher expenses and absence of one-time gains (previous year included Rs 1,010 Lacs from PPE sale). Standalone revenue grew 17% to Rs 5,034.73 Lacs. On consolidated basis, revenue rose 16% to Rs 14,059.48 Lacs with PAT declining to Rs 786.08 Lacs (from Rs 1,090.75 Lacs). The pharmaceutical segment reported losses while the chemical manufacturing segment drove overall profitability. The company has two reportable segments: Pharmaceuticals and Chemical Manufacturing. Auditors issued unmodified opinions confirming clean audits for both standalone and consolidated results.
The standalone loss despite revenue growth signals cost pressures in the pharma business. However, the consolidated profit and strong revenue growth indicate the chemical manufacturing subsidiary (Resonance Specialties Limited) is the earnings driver. Clean auditor opinions without any going concern doubts provide some comfort for investors despite the profit decline.